702 related articles for article (PubMed ID: 12660501)
1. Interleukin-2 receptor blockade in cardiac transplantation: influence of HLA-DR locus incompatibility on treatment efficacy.
Lietz K; John R; Beniaminovitz A; Burke EM; Suciu-Foca N; Mancini DM; Edwards NM; Itescu S
Transplantation; 2003 Mar; 75(6):781-7. PubMed ID: 12660501
[TBL] [Abstract][Full Text] [Related]
2. The effects of HLA mismatching and immunosuppressive therapy on early rejection outcome in pediatric heart transplant recipients.
Herzberg GZ; Rossi AF; Courtney M; Gelb BD
J Heart Lung Transplant; 1998 Dec; 17(12):1195-200. PubMed ID: 9883760
[TBL] [Abstract][Full Text] [Related]
3. Independent risk factors predicting acute graft rejection in cardiac transplant recipients treated by triple drug immunosuppression.
Laufer G; Miholic J; Laczkovics A; Wollenek G; Holzinger C; Hajek-Rosenmeier A; Wuzl G; Schreiner W; Buxbaum P; Wolner E
J Thorac Cardiovasc Surg; 1989 Dec; 98(6):1113-21. PubMed ID: 2586129
[TBL] [Abstract][Full Text] [Related]
4. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody.
Beniaminovitz A; Itescu S; Lietz K; Donovan M; Burke EM; Groff BD; Edwards N; Mancini DM
N Engl J Med; 2000 Mar; 342(9):613-9. PubMed ID: 10699160
[TBL] [Abstract][Full Text] [Related]
5. Immunoglobulin M-to-immunoglobulin G anti-human leukocyte antigen class II antibody switching in cardiac transplant recipients is associated with an increased risk of cellular rejection and coronary artery disease.
Lietz K; John R; Burke E; Schuster M; Rogers TB; Suciu-Foca N; Mancini D; Itescu S
Circulation; 2005 Oct; 112(16):2468-76. PubMed ID: 16230499
[TBL] [Abstract][Full Text] [Related]
6. HLA-DR mismatching correlates with early cardiac allograft rejection, incidence, and graft survival when high-confidence-level serological DR typing is used.
De Mattos AM; Head MA; Everett J; Hosenpud J; Hershberger R; Cobanoglu A; Ott G; Ratkovec R; Norman DJ
Transplantation; 1994 Feb; 57(4):626-30. PubMed ID: 8116051
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group.
Vincenti F; Kirkman R; Light S; Bumgardner G; Pescovitz M; Halloran P; Neylan J; Wilkinson A; Ekberg H; Gaston R; Backman L; Burdick J
N Engl J Med; 1998 Jan; 338(3):161-5. PubMed ID: 9428817
[TBL] [Abstract][Full Text] [Related]
8. Additive value of immunologic monitoring to histologic grading of heart allograft biopsy specimens: implications for therapy.
Fisher PE; Suciu-Foca N; Ho E; Michler RE; Rose EA; Mancini D
J Heart Lung Transplant; 1995; 14(6 Pt 1):1156-61. PubMed ID: 8719463
[TBL] [Abstract][Full Text] [Related]
9. HLA-DR matching in organ allocation: balance between waiting time and rejection in pediatric kidney transplantation.
Vu LT; Baxter-Lowe LA; Garcia J; McEnhill M; Summers P; Hirose R; Lee M; Stock PG
Arch Surg; 2011 Jul; 146(7):824-9. PubMed ID: 21768429
[TBL] [Abstract][Full Text] [Related]
10. Induction therapy after cardiac transplantation: a comparison of anti-thymocyte globulin and daclizumab in the prevention of acute rejection.
Carlsen J; Johansen M; Boesgaard S; Andersen CB; Arendrup H; Aldershvilet J; Mortensen SA
J Heart Lung Transplant; 2005 Mar; 24(3):296-302. PubMed ID: 15737756
[TBL] [Abstract][Full Text] [Related]
11. Aortic valve allograft structural deterioration is associated with a subset of antibodies to human leukocyte antigens.
Dignan R; O'Brien M; Hogan P; Thornton A; Fowler K; Byrne D; Stephens F; Harrocks S
J Heart Valve Dis; 2003 May; 12(3):382-90; discussion 390-1. PubMed ID: 12803340
[TBL] [Abstract][Full Text] [Related]
12. Utility of posttransplantation panel-reactive antibody measurements for the prediction of rejection frequency and survival of heart transplant recipients.
George JF; Kirklin JK; Shroyer TW; Naftel DC; Bourge RC; McGiffin DC; White-Williams C; Noreuil T
J Heart Lung Transplant; 1995; 14(5):856-64. PubMed ID: 8800720
[TBL] [Abstract][Full Text] [Related]
13. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients.
Meng HL; Jin XB; Li XT; Wang HW; Lü JJ
Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748
[TBL] [Abstract][Full Text] [Related]
14. Ten-year follow-up of a prospective, randomized trial of BT563/bb10 versus anti-thymocyte globulin as induction therapy after heart transplantation.
Bonaros N; Dunkler D; Kocher A; Imhof M; Grimm M; Zuckermann A; Wolner E; Laufer G
J Heart Lung Transplant; 2006 Sep; 25(9):1154-63. PubMed ID: 16962480
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipients.
Lim WH; Chadban SJ; Campbell S; Dent H; Russ GR; McDonald SP
Nephrology (Carlton); 2010 Apr; 15(3):368-76. PubMed ID: 20470309
[TBL] [Abstract][Full Text] [Related]
16. Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporine, and corticosteroids.
Kobashigawa J; David K; Morris J; Chu AH; Steffen BJ; Gotz VP; Gordon RD
Transplant Proc; 2005 Mar; 37(2):1333-9. PubMed ID: 15848713
[TBL] [Abstract][Full Text] [Related]
17. Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized study.
Stratta RJ; Alloway RR; Lo A; Hodge E
Transplantation; 2003 Apr; 75(8):1260-6. PubMed ID: 12717213
[TBL] [Abstract][Full Text] [Related]
18. HLA-DR matching improves survival after heart transplantation: is it time to change allocation policies?
Kaczmarek I; Deutsch MA; Rohrer ME; Beiras-Fernandez A; Groetzner J; Daebritz S; Schmoeckel M; Spannagl M; Meiser B; Reichart B
J Heart Lung Transplant; 2006 Sep; 25(9):1057-62. PubMed ID: 16962466
[TBL] [Abstract][Full Text] [Related]
19. Rejection in heart transplantation strongly correlates with HLA-DR antigen mismatch.
Sheldon S; Hasleton PS; Yonan NA; Rhaman AN; Deiraniya AK; Campbell CS; Brooks NH; Dyer PA
Transplantation; 1994 Sep; 58(6):719-22. PubMed ID: 7940693
[TBL] [Abstract][Full Text] [Related]
20. HLA mismatches remain risk factors for acute kidney allograft rejection in patients receiving quadruple immunosuppression with anti-interleukin-2 receptor antibodies.
Wissing KM; Fomegné G; Broeders N; Ghisdal L; Hoang AD; Mikhalski D; Donckier V; Vereerstraeten P; Abramowicz D
Transplantation; 2008 Feb; 85(3):411-6. PubMed ID: 18322434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
